Adenosine receptor expression in two different human cancer cell lines at molecular level

Iranian Journal of Cancer Prevention

Volumn 3, Issue 3, 2010, Pages 111-116

  Panjehpour, M ^a   Movahedian, A ^a   Sadeghi, H ^a   Eghbali, B ^a   Yekdaneh, A ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adenosine receptor; Cell line; Human cancer; Lung; Prostate; RT PCR

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; COMPLEMENTARY DNA; MESSENGER RNA;

AGAR GEL ELECTROPHORESIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CULTURE MEDIUM; DNA SEQUENCE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROSTATE CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

EID: 77957136681     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther. 2003; 100(1):31-48.
2. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther. 2008; 117(1):123-140.
3. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. 25. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001; 53(4):527-552.
4. Panjehpour M, Karami-Tehrani F. Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. Oncol Res. 2007; 16(12):575-585.
5. Panjehpour M, Castro M, Klotz KN. Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal. Br J Pharmacol. 2005; 145(2):211-218.
6. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, et al. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol. 2002; 119(4):923-933.
7. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol. 2002; 22(3):364-373.
8. Tey HB, Khoo HE, Tan CH. Adenosine modulates cell growth in human epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun.1992; 187(3):1486-1492.
9. Yao Y, Sei Y, Abbracchio MP, Jiang JL, Ki m YC, Jacobson KA. Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem Biophys Res Commun. 1997; 232(2):317-322.
10. Shand RL, Gelmann EP. Molecular biology of prostate-cancer pathogenesis.: Curr Opin Urol. 2006; 16(3):123-131.
11. Alvarez M, Roman E, Santos ES, Raez LE. New targets for non-small-cell lung cancer therapy. Expert Rev Anticancer Ther. 2007; 7(10):1423-1437.
12. Nandigama R, Padmasekar M, Wartenberg M, Sauer H. Feed forward cycle of hypotonic stress-induced ATP release, purinergic receptor activation, and growth stimulation of prostate cancer cells. J Biol Chem. 2006; 281(9):5686-5693.
13. Janssens R, Boeynaems JM. Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br J Pharmacol. 2001; 132(2):536-546.
14. Zimmermann H. Extracellular purine metabolism. Drug Dev Res. 1996; 39(3-4):337-352.
15. Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger A, Ohana G, Harish A, Merimski O, Barer F, Fishman P. The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res. 2004; 10(13):4472-4479.
16. Gessi S, Merighi S, Varani K, Cattabriga E, Benini A, Mirandola P, et al. Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A (3) adenosine subtype. J Cell Physiol. 2007; 211(3):826-836.
17. Panjehpour M, Karami-Tehrani F. An adenosine analog (IB-MECA) inhibits anchorage-dependent cell growth of various human breast cancer cell lines. Int J Biochem Cell Biol. 2004; 36(8):1502-1509.
18. Fishman P, Bar-Yehuda S, Ardon E, Rath-Wolfson L, Barrer F, Ochaion A, et al. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res. 2003; 23(3A):2077-2083.
19. Ohana G, Bar-Yehuda S, Barer F, Fishman P. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol. 2001; 186(1):19-23.
20. Preston A, Frydenberg M, Haynes JM. A1 and A2A adenosine receptor modulation of alpha 1-adrenoceptormediated contractility in human cultured prostatic stromal cells. Br J Pharmacol. 2004; 141(2):302-310.
21. Matot I, Weiniger CF, Zeira E, Galun E, Joshi BV, Jacobson KA. A3 adenosine receptors and mitogenactivated protein kinases in lung injury following in vivo reperfusion. Crit Care. 2006; 10(2):R65.
22. Zhong H, Shlykov SG, Molina JG, Sanborn BM, Jacobson MA, Tilley SL, et al. Activation of murine lung mast cells by the adenosine A3 receptor. J Immunol. 2003; 171(1):338-345.